Movatterモバイル変換

KP-1461

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

KP-1461
Clinical data

Drug class	Reverse transcriptase inhibitor
Legal status
Legal status	Investigational
Identifiers
CAS Number	815588-85-3
PubChemCID	51003457
DrugBank	05644
ChemSpider	32702166
UNII	3PEN569TJP
CompTox Dashboard(EPA)	DTXSID101112194
Chemical and physical data
Formula	C₁₆H₂₃N₄O₆
Molar mass	367.382 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCCCCCCOC(=O)NC1=NCN(C(=O)N1)[C@H]2C[C@@H]([C@H](O2)CO)O
InChI InChI=1S/C16H28N4O6/c1-2-3-4-5-6-7-25-16(24)19-14-17-10-20(15(23)18-14)13-8-11(22)12(9-21)26-13/h11-13,21-22H,2-10H2,1H3,(H2,17,18,19,23,24)/t11-,12+,13+/m0/s1 Key:SZWIAFVYPPMZML-YNEHKIRRSA-N

KP-161 is an experimental antiviral drug being studied for the treatment ofHIV/AIDS.^[1] It belongs to the class ofnucleoside reverse transcriptase inhibitors.^[2]

KP-1461 is aprodrug of the active antiviral agent KP-1212.^[3]

^"KP-1461".AIDSinfo. U.S. Department of Health and Human Services. Archived fromthe original on 2019-08-11. Retrieved2018-09-04.
^Harris K, Sergueev D, Reno J (December 2006)."The chemistry and biology of KP-1461, a selective nucleoside mutagen for HIV therapy".Retrovirology.3 (Suppl 1): S13.doi:10.1186/1742-4690-3-S1-S13.PMC 1716920.
^"KP-1461".DrugBank. Canadian Institutes of Health Research.

Thisantiinfective drug article is astub. You can help Wikipedia byexpanding it.

Entry/fusion inhibitors
(Discovery and development)

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Protease Inhibitors (PI)
(Discovery and development)

1^st generation	Amprenavir (APV)^‡ Fosamprenavir (FPV) Indinavir (IDV)^◊ Lopinavir (LPV) Nelfinavir (NFV)^◊ Ritonavir (RTV)^# Saquinavir (SQV)^◊
2^nd generation	Atazanavir (ATV)°^# Darunavir (DRV)°^# Tipranavir (TPV)^◊ TMC-310911^§

Non-nucleoside (NNRTI)
(Discovery and development)

1^st generation	Efavirenz (EFV)^# Nevirapine (NVP)^# Delavirdine (DLV)^‡
2^nd generation	diarylpyrimidines Dapivirine (DPV) Etravirine (ETR) Rilpivirine (RPV) Doravirine (DOR) Elsulfavirine (ESV)

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)
Transcription inhibitors	Tat antagonists
Translation inhibitors	Trichosanthin
BNAbs	Elipovimab
Other	Abzyme BIT225^† Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Fosdevirine^† Griffithsin Hydroxycarbamide KP-1461^† Miltefosine Portmanteau inhibitors Scytovirin Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor
Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

°DHHSrecommendedinitial regimen options.^◊Formerly or rarely used agent.

Hidden categories: